CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug

PartnershipHM17321Positive
AI Analysis

Summary

Roche's Genentech subsidiary will gain access to Hanmi's investigational weight loss drug HM17321 in a deal valued up to $2.3 billion, targeting both weight loss and lean mass improvement.

Importance:7/10
Sentiment:
0.70
weight losslean masslicensing dealRocheHanmiGLP-1
Related Companies

Read the original article

Published by BioSpace on August 24, 2026 12:57 PM

Read Original